Kamada announces financial results for the three and six months ended June 30, 2014.
Kamada management will host an investment community conference call today beginning at 8:30 a.m. Eastern time to discuss these results and answer questions. To participate in the conference call, please find dialing details below.
Kamada management will host an investment community conference call on Thursday, August 14, 2014 beginning at 8:30 a.m. Eastern time
Positive clinically meaningful efficacy signs in the inhaled AAT group including an approximate 50% reduction in severe exacerbation rates versus placebo
Continues with plans to submit for licensure in Europe in Q4 2014
Conference call begins at 8:30 a.m. Eastern time
Kamada announces financial results for the three months ended March 31, 2014
The improved infusion rate is highly important because it reduces the overall time from preparation to finish, which is key for AATD patients who are using this therapy chronically and for life.
Lowers time from preparation to finish for patients with Alpha-1 Antitrypsin Deficiency by more than 75%
The POC study is a Phase I/II trial of 24 patients with steroid-resistant GVHD following allogeneic bone-marrow stem cell transplant who will receive six to ten doses of intravenously delivered Glassia to determine safety, optimal dose and clinical response.
Preliminary human and animal studies indicate that AAT may considerably reduce the severity of GVHD, which is one of the key, life threatening complications of allogeneic stem cell transplantation.
NESS ZIONA, Israel (March 24, 2014) – Kamada Ltd. (Nasdaq and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation of a new Phase 2 U.S. clinical trial of its proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD, or Inherited Emphysema). This trial is […]
Affirms plans for EMA submission in the second half of 2014